AUTHORS
Susan Bal, MD, Luciano J. Costa, MD, PhD2, Nizar Bahlis, MD3, Omar Nadeem, MD4, Christine Chen, MHPE, MD, FRCPC5, Jingmei Hsu, MD6, Myo Htut, MD7, Krina Patel Jr, MD, MSc8, David S Siegel, MD, PhD9, J Erin Wiedmeier-Nutor, MD,MPH10, Christopher D'Angelo, MD11, Ehsan Malek, MD12, Scott R Solomon, MD13, Tim Campbell, MD, PhD14, Jaclyn Davis, MD15, Ziyan Guo, PhD16, Jennifer Han17, Hongxiang Hu18, Krishna R. Juluri19, Jessica Katz, MD, PhD20, Liane Kuo, PharmD21, Safiyyah Ziyad, PhD22, Sham Mailankody, MBBS23
AFFILIATIONS
1 University of Alabama at Birmingham-the University of Alabama at Birmingham, Birmingham, Alabama, United States
2 University of Alabama at Birmingham-the University of Alabama at Birmingham, Birmingham, Alabama, United States
3 Arnie Charbonneau Cancer Institute, Calgary, Alberta, Canada, University of Calgary, Calgary, Alberta, Canada
4 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
5 Princess Margaret Cancer Centre, Toronto, Ontario, Canada
6 New York University, New York, New York, United States
7 City of Hope Comprehensive Cancer Center, Duarte, California, United States
8 University of Texas MD Anderson Cancer Center, Houston, Texas, United States
9 Quest Diagnostics John Theurer Cancer Center - Oncology Center HUMC, Hackensack, New Jersey, United States
10 Mayo Clinic, Phoenix, Arizona, United States
11 University of Nebraska, Omaha, Nebraska, United States
12 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
13 Northside Hospital Cancer Institute, Atlanta, Georgia, United States
14 Bristol Myers Squibb, Princeton, New Jersey, United States
15 Bristol Myers Squibb, Princeton, New Jersey, United States
16 Bristol Myers Squibb, Princeton, New Jersey, United States
17 Bristol Myers Squibb, Princeton, New Jersey, United States
18 Bristol Myers Squibb, Princeton, New Jersey, United States
19 Bristol Myers Squibb, Princeton, New Jersey, United States
20 Bristol Myers Squibb, Princeton, New Jersey, United States
21 Bristol Myers Squibb, Princeton, New Jersey, United States
22 Bristol Myers Squibb, Princeton, New Jersey, United States
23 Memorial Sloan Kettering Cancer Center, New York, New York, United States
ABSTRACT
Introduction: Arlocabtagene autoleucel (arlo-cel)—an investigational GPRC5D-targeted CAR T cell therapy—demonstrated efficacy (ORR, 87%; mDOR, 18.0 mo) in patients (pts) with relapsed/refractory multiple myeloma (RRMM) in a first-in-human, ph1 study (NCT04674813). While ORR was high, combining arlo-cel with other therapies may induce even deeper, more durable responses. Mezigdomide (MEZI), an investigational oral CELMoD optimized for Ikaros/Aiolos degradation, showed clinically meaningful PFS benefit when combined with Kd in pts with RRMM in the ph3 SUCCESSOR-2 trial (NCT05552976). Elranatamab (ELRA), a bispecific BCMA-directed CD3 T-cell engager (TCE), demonstrated efficacy (ORR, 61%) in the ph2 MagnetisMM-3 (NCT04649359) trial. All 3 agents have distinct tumoricidal mechanisms; MEZI and ELRA are also immunostimulatory. In MM, ELRA stimulates endogenous T cells and may enable dual-antigen targeting (BCMA and GPRC5D) when combined with arlo-cel, while preclinical data have shown MEZI can enhance T-cell function and CAR T cell activity.
This multiarm trial (NCT06121843) will evaluate arlo-cel combinations, including with MEZI (arm B) or ELRA (arm D) as maintenance therapy and MEZI plus dexamethasone (DEX) as preleukapheresis conditioning followed by arlo-cel (arm E). In arms B and D, safety, tolerability, and the RP2D for each combination will be determined, as will the preliminary efficacy and PK for pts with RRMM. Arm E will assess the impact of MEZI/DEX preleukapheresis conditioning on arlo-cel and its safety and preliminary efficacy.
Methods: This multicenter, open-label, ph1 trial comprises dose-finding (part [P] 1) and dose-expansion (P2) cohorts. Eligible pts are aged ≥18 y, have measurable RRMM, and an ECOG PS of 0–1. Pts must have received prior antimyeloma regimens; ≥3 (P1), 1–3 (P2, arms B and D), or ≥1 (P2, arm E). Required prior therapies include an immunomodulatory drug (IMiD), proteasome inhibitor (PI), anti-CD38 monoclonal antibody, and, if eligible, an autologous stem cell transplant (P1), an IMiD and PI (P2, arms B and D), or a PI, IMiD, anti-CD38 mAb, and a BCMA TCE, the latter as the most recent therapy (P2, arm E). Key exclusion criteria are prior GPRC5D-targeted therapy (all arms), MEZI (arms B and E), ELRA (arm D), and BCMA-targeted therapy (P2, arm D). All pts will receive lymphodepleting chemotherapy (LDC) prior to arlo-cel infusion; bridging therapy is mandatory after leukapheresis and prior to LDC.
In P1, all pts will receive an arlo-cel IV infusion on day 1 (D1; 75×106 [dose level 1] or 150×106 [dose level 2]). MEZI or ELRA may begin as early as D29 after arlo-cel (arms B and D). MEZI (0.6 mg oral QD) is administered on D1–21 of 28-day cycles (C). ELRA is administered SC for a fixed duration of 12 cycles with step-up dosing in C0 (12 mg and 32 mg), followed by 76 mg on C0D8, then every 2 weeks followed by every 4 weeks. Dose escalation/de-escalation uses a Bayesian optimal interval design, with dose-limiting toxicities (DLTs) evaluated for 28 days after first exposure to arlo-cel and the combination therapy. Pts are to receive study treatment until PD, treatment completion, an AE requiring discontinuation, or consent withdrawal. RP2D selection will consider the DLT rate across dose levels and cumulative safety, efficacy, and PK/PD data.
In P2, safety and efficacy will be evaluated in arms B and D for arlo-cel plus MEZI or ELRA at the selected RP2D. In arm E, safety and efficacy of arlo-cel (75×10⁶ CAR T cells) will be evaluated in pts receiving 1 cycle of MEZI (1 mg administered preleukapheresis on D1−21 of a 28-day cycle) and DEX (40 mg on D1, 8, and 15). A reduced MEZI dose (ie, 0.6 mg) may be tested.
Primary endpoints are frequency and severity of AEs, serious AEs, AEs of special interest, AEs leading to discontinuation or death, and RP2D establishment for each combination. Secondary endpoints include overall response rate, CRR, VGPRR, and arlo-cel kinetics in peripheral blood. Pts will undergo post-treatment follow-up for response, survival, long-term toxicity, and lentiviral vector safety, with rollover to a separate long-term follow-up trial for ≤15 y after arlo-cel infusion. Anticipated enrollment is 187 pts in the US and Canada.
Results: Enrollment began in February 2024 and is ongoing.
Conclusions: This trial will evaluate novel arlo-cel combinations including MEZI/DEX preleukapheresis and MEZI or ELRA maintenance strategies to potentially improve arlo-cel responses in pts with RRMM.
DISCLOSURES
Susan Bal, MD: AbbVie, Adaptive Biotechnologies, Amyloid Foundation, AstraZeneca, BeiGene, Bristol Myers Squibb Foundation, Bristol Myers Squibb/Celgene, Fate Therapeutics, Janssen Oncology, Kite/Arcellx, MJH Life Sciences, and Pfizer - Consultancy (Includes expert testimony)